Barclays Lowers bluebird bio (NASDAQ:BLUE) Price Target to $2.00

bluebird bio (NASDAQ:BLUE - Free Report) had its target price reduced by Barclays from $4.00 to $2.00 in a research report released on Friday,Benzinga reports. They currently have an overweight rating on the biotechnology company's stock.

A number of other equities research analysts also recently weighed in on the company. JPMorgan Chase & Co. downgraded bluebird bio from a "neutral" rating to an "underweight" rating in a research report on Friday. Wells Fargo & Company lowered their price target on shares of bluebird bio from $3.00 to $2.00 and set an "equal weight" rating on the stock in a report on Wednesday, September 25th. Royal Bank of Canada reiterated a "sector perform" rating and set a $4.00 price objective on shares of bluebird bio in a research note on Thursday, August 15th. Cantor Fitzgerald reissued a "neutral" rating on shares of bluebird bio in a research report on Monday, September 16th. Finally, StockNews.com initiated coverage on shares of bluebird bio in a report on Sunday, November 10th. They issued a "sell" rating on the stock. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $3.03.

bluebird bio Stock Down 11.5 %

NASDAQ BLUE traded down $0.04 during trading on Friday, reaching $0.32. 9,118,886 shares of the company's stock traded hands, compared to its average volume of 7,439,042. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.68 and a quick ratio of 0.57. The company's 50 day simple moving average is $0.49 and its two-hundred day simple moving average is $0.79. bluebird bio has a 12-month low of $0.32 and a 12-month high of $5.53. The firm has a market cap of $62.21 million, a price-to-earnings ratio of -0.14 and a beta of 0.76.

bluebird bio (NASDAQ:BLUE - Get Free Report) last issued its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. The business had revenue of $18.57 million during the quarter. bluebird bio had a negative return on equity of 207.25% and a negative net margin of 567.29%. As a group, sell-side analysts forecast that bluebird bio will post -1.41 EPS for the current fiscal year.

Hedge Funds Weigh In On bluebird bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of bluebird bio by 38.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company's stock valued at $416,000 after purchasing an additional 90,139 shares during the period. SG Americas Securities LLC increased its holdings in bluebird bio by 458.8% in the 1st quarter. SG Americas Securities LLC now owns 80,032 shares of the biotechnology company's stock worth $102,000 after buying an additional 65,710 shares during the period. Vanguard Group Inc. raised its position in bluebird bio by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company's stock worth $13,438,000 after buying an additional 1,723,081 shares during the last quarter. American International Group Inc. raised its position in bluebird bio by 77.4% during the 1st quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company's stock worth $121,000 after buying an additional 41,177 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in bluebird bio by 113.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 29,113 shares during the period. Hedge funds and other institutional investors own 87.43% of the company's stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.